Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Hemant S. Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B. Alkhateeb, Susan Bal, Mohamed A. Kharfan-Dabaja, Bhagirathbhai Dholaria, Francine Foss, Lohith Gowda, Deepa Jagadeesh, Craig Sauter, Muhammad Bilal Abid, Mahmoud Aljurf, Farrukh T. Awan, Ulrike Bacher, Sherif M. Badawy, Minoo Battiwalla, Chris Bredeson, Jan Cerny, Saurabh ChhabraAbhinav Deol, Miguel Angel Diaz, Nosha Farhadfar, César Freytes, James Gajewski, Manish J. Gandhi, Siddhartha Ganguly, Michael R. Grunwald, Joerg Halter, Shahrukh Hashmi, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Antonio Martin Jimenez-Jimenez, Matt Kalaycio, Rammurti Kamble, Maxwell M. Krem, Hillard M. Lazarus, Aleksandr Lazaryan, Joseph Maakaron, Pashna N. Munshi, Reinhold Munker, Aziz Nazha, Taiga Nishihori, Olalekan O. Oluwole, Guillermo Ortí, Dorothy C. Pan, Sagar S. Patel, Attaphol Pawarode, David Rizzieri, Nakhle S. Saba, Bipin Savani, Sachiko Seo, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Baldeep Wirk, Betul Oran, Ryotaro Nakamura, Bart Scott, Wael Saber

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patient and transplantation characteristics and outcomes after alloHCT are sparse. In this study, we evaluated outcomes of alloHCT in patients with T-PLL and attempted to identify predictors of post-transplantation relapse and survival. We conducted an analysis of data using the Center for International Blood and Marrow Transplant Research database on 266 patients with T-PLL who underwent alloHCT between 2008 and 2018. The 4-year rates of overall survival (OS), disease-free survival (DFS), relapse, and treatment-related mortality (TRM) were 30.0% (95% confidence interval [CI], 23.8% to 36.5%), 25.7% (95% CI, 20% to 32%), 41.9% (95% CI, 35.5% to 48.4%), and 32.4% (95% CI, 26.4% to 38.6%), respectively. In multivariable analyses, 3 variables were associated with inferior OS: receipt of a myeloablative conditioning (MAC) regimen (hazard ratio [HR], 2.18; P < .0001), age >60 years (HR, 1.61; P = .0053), and suboptimal performance status, defined by Karnofsky Performance Status (KPS) <90 (HR, 1.53; P = .0073). Receipt of an MAC regimen also was associated with increased TRM (HR, 3.31; P < .0001), an elevated cumulative incidence of grade II-IV acute graft-versus-host disease (HR, 2.94; P = .0011), and inferior DFS (HR, 1.86; P = .0004). Conditioning intensity was not associated with relapse; however, stable disease/progression was correlated with increased risk of relapse (HR, 2.13; P = .0072). Both in vivo T cell depletion (TCD) as part of conditioning and KPS <90 were associated with worse TRM and inferior DFS. Receipt of total body irradiation had no significant effect on OS, DFS, or TRM. Our data show that reduced-intensity conditioning without in vivo TCD (ie, without antithymocyte globulin or alemtuzumab) before alloHCT was associated with long-term DFS in patients with T-PLL who were age ≤60 years or who had a KPS >90 or chemosensitive disease.

Original languageEnglish
Pages (from-to)187.e1-187.e10
JournalTransplantation and Cellular Therapy
Issue number4
StatePublished - Apr 2022

Bibliographical note

Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy


  • Allogeneic stem cell transplant
  • Prolymphocytic leukemia
  • T-PLL

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Medicine
  • Hematology
  • Cell Biology
  • Transplantation


Dive into the research topics of 'Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research'. Together they form a unique fingerprint.

Cite this